COVID-19 mortality reduced 4X (chart looks like 2X) by large, infrequent doses of Vitamin D in France

Vitamin D supplementation prior to or during COVID-19 associated with better 3-month survival in geriatric patients: Extension phase of the GERIA-COVID study

J Steroid Biochem Mol Biol. 2021 Jul 28;105958. doi: 10.1016/j.jsbmb.2021.105958

Cédric Annweiler 1, Mélinda Beaudenon 2, Romain Simon 2, Mialy Guenet 2, Marie Otekpo 2, Thomas Célarier 3, Jennifer Gautier 2, GERIA-COVID study group

Note: This study combined all infrequent dosing into intervention data * 50,000IU per month, or * 80,000IU or 100,000IU or 200,000IU every 2-3 months Note: The vitamin D levels did not rise very much for those getting this small amount of vitamin D Note: 2-3 months dosing produces less than half the response as monthly dosing 1. # Items in both categories Virus and Loading Dose are listed here: {category} --- Loading Dose of Vitamin D category has the following {include} Note: >70% of the RCT using Vitamin D to fight COVID-19 are using at least 100,000 IU during the first week

📄 Download the PDF from VitaminDWiki

VitaminDWiki suspect that there is data error.
The above table shows that those supplementing had LOWER vitamin D levels

Background: The objective of this extension phase of the quasi-experimental GERIA-COVID study was to determine whether vitamin D3 supplementation taken prior to or during COVID-19 was associated with better 3-month survival in geriatric patients hospitalized for COVID-19.

Methods: Intervention group was defined as all participants supplemented with vitamin D3 prior to or during COVID-19 (n = 67). Supplements were either bolus vitamin D3 (ie, 50,000IU per month, or 80,000IU or 100,000IU or 200,000IU every 2-3 months), or daily supplementation with 800IU. Comparator group involved those without vitamin D supplements (n = 28). Outcome was 3-month mortality. Covariables were age, sex, functional abilities, history of malignancies, cardiomyopathy, undernutrition, number of acute health issues, antibiotics use, systemic corticosteroids use, and 25(OH)D concentration.

Results: 76.1% (n = 51) of participants survived at 3 months in Intervention group, compared to only 53.6% (n = 15) in Comparator group (P = 0.03). The fully-adjusted hazard ratio for 3-month mortality was HR = 0.2395%CI:0.09;0.58 in Intervention group compared to Comparator group. Intervention group had also longer survival time (log-rank P = 0.008).

Conclusions: Vitamin D3 supplementation was associated with better 3-month survival in older COVID-19 patients.